|
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma Clinical research trials and Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma. Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma clinical trial. Subjects frequently obtain the most expert healthcare possible for their Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma
For Condition: Melanoma,Neoplasm Metastasis
Status: Completed
Sponsor(s): Celgene Corporation ,
Synopsis: Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Understand and voluntarily sign an informed consent form. - Able to adhere to the study visit schedule and other protocol requirements. - Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy. - Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug. - Patients with active brain disease, or newly diagnosed brain metastases, within 4 weeks prior to the start of study treatment are excluded.
Total Enrollment: 274
Location and Contact Information:
MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
Spectrum Health
Grand Rapids, Michigan, 49503
United States
Cancer Care Manitoba
Winnipeg, Manitoba, R3E 0V9
Canada
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Canada
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
Canada
Penn State Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
United States
Massachusetts General Hospital
Boston, Massachusetts, 02214-2698
United States
Lutheran General
Park Ridge, Illinois, 60068-1270
United States
Washington University School of Medicine
St. Louis, Missouri, 63110
United States
Carle Clinic
Urbana, Illinois, 61801
United States
University of Colorado
Aurora, Colorado, 80010
United States
The Linder Clinical Trial Center
Cincinnati, Ohio, 45219
United States
Biomedical Research Alliance of New York
New York City, New York, 10016
United States
Beth Israel Deaconess Medical Ctr
Boston, Massachusetts, 02215-5400
United States
Outpatient Clinic
Santa Monica, California, 90404
United States
UPMC Cancer Pavillion
Pittsburgh, Pennsylvania, 15232
United States
Sarah Cannon Cancer Center
Nashville, Tennessee, 37203-1632
United States
Lakeland Regional Cancer Center
Lakeland, Florida, 33804-1057
United States
Qell Health Sciences Center
Halifax, Nova Scotia, B3H 2y9
Canada
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
United States
University of Southern California Norris Cancer Center
Los Angeles, California, 90089
United States
UCLA
Los Angeles, California, 90095-6956
United States
Mount Sinai Comprehensive Cancer Center
Miami, Florida, 33140
United States
Melanoma Center of St Louis
St. Louis, Missouri, 63131
United States
Memorial Sloan Kettering Cancer Center
New York City, New York, 10021
United States
The Harold Lever Regional Cancer Center
Waterbury, Connecticut, 06708
United States
L'Hotel Dieu de Quebec
Quebec, , PQ G1R 2J6
Canada
University of Arizona Cancer Center
Tucson, Arizona, 85724
United States
Ellis Fischel Cancer Center
Columbia, Missouri, 65203
United States
St. Francis Memorial Hospital
San Francisco, California, 94109
United States
Tom Baker Cancer Center
Calgary, Alberta, T2N 4N2
Canada
Additional Information:
Study ID Numbers: CDC-5013-MEL-001;
Study Start Date: January 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00055562
Other Melanoma Studies:
1. Immunization of HLA-A201 Patients with Metastatic Melanoma Using a Combination of Immunodominant Peptides from Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
2. Treatment of Patients with Cancer with Genetically Modified Salmonella Typhimurium Bacteria
3. Liver Perfusion of Melphalan in Inoperable Liver Cancer
4. Treatment of Patients with Metastatic Melanoma Using Cloned Peripheral Blood Lymphocytes Sensitized In Vitro to the gp209-2M Immunodominant Peptide
5. A Phase I/II Trial of Vaccination with Mutant Ras Peptide Pulsed Dendritic Cells in the Treatment of HLA A2.1 Positive Patients with Colorectal Cancer
Related Studies:
Other Melanoma Clinical Trials
Other Ontario Clinical Trials
Other Toronto Clinical Trials
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma
|
|
|
|
|
|
|
|